

6-B&C, Pil Court, 6th Floor,  
111, M. Karve Road, Churchgate,  
Mumbai - 400 020.  
Tel.: (+91-22) 4311 5000  
Fax : 4311 5050

12-B, Baldota Bhavan, 5th Floor,  
117, M. Karve Road, Churchgate,  
Mumbai - 400 020.  
Tel.: (+91-22) 4311 6000  
Fax : 4311 6060

### INDEPENDENT AUDITORS' REVIEW REPORT

#### TO THE BOARD OF DIRECTORS OF GUJARAT THEMIS BIOSYN LIMITED

1. We have reviewed the accompanying statement of unaudited financial results of 'Gujarat Themis Biosyn Limited' ("the Company") for the quarter ended June 30, 2017 ("the Statement") being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular no. CIR/CFD/FAC/62/2016 dated July 5, 2016. The Statement which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the Companies (Indian Accounting Standard) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognised accounting practices and policies. Our responsibility is to issue a report on the statement based on our review.
2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. **Basis of qualified conclusion**
  - (i) The outstanding balances in respect of certain balances of loans & advances, trade receivables, liability for expenses, trade payables and creditors for capital expenditure are subject to confirmation from respective parties and consequential reconciliation and adjustment arising there from, if any [Refer note no. 5(a) of the Statement]. Consequential impact thereof on the financial results is not ascertainable. In respect of above matter, our audit report for the year ended March 31, 2017 was similarly qualified.
  - (ii) The Company has not determined and identified significant components of fixed assets as prescribed under the provisions of para 4(a) under the heading Notes after Part C in Schedule II of the Companies Act, 2013 and Indian Accounting Standard (Ind AS) 16- "Property, Plant and Equipment". The impact of the same on financial results is not ascertainable. [Refer note no. 5(b) of the Statement]. In respect of above matter, our audit report for the year ended March 31, 2017 was similarly qualified.



(iii) The Company has provided the gratuity expense of Rs.1.85 lakhs and leave encashment expense of Rs.1.73 lakhs on estimated basis and not on actuarial basis and reclassification on account of re-measurement of post-employment benefit obligations (gain)/loss in respect of gratuity, an item that will not be classified to Profit & Loss under the head 'Other Comprehensive Income' has not been made. This is not in accordance with Indian Accounting Standard 19 "Employee Benefits". The impact of the same on financial results is not ascertainable. [Refer note no. 4 of the Statement].

4. Based on our review conducted as above, except for the possible effects of the matters described in the Basis for qualified conclusion paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable Indian Accounting Standards (Ind AS) read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as modified by Circular no. CIR/CFD/FAC/62/2016 dated July 5, 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

**5. Other Matter**

We were neither engaged to review, nor have we reviewed the comparative figures including the reconciliation to the Total Comprehensive Income for the quarter ended on June 30, 2016 and accordingly, we do not express any conclusion on the results in the statement for the quarter ended June 30, 2016 as set out in the note 1 to the Statement, these figures have been furnished by the management of the company.

Our conclusion on the results and our report is not modified in respect of the above matter.

For **KHANDELWAL JAIN & CO.**  
Chartered Accountants  
Firm's Regn. No. 105049W



**(NARENDRA JAIN)**  
**PARTNER**  
Membership No.:048725



Place: Mumbai  
Date : September 4, 2017

**GUJARAT THEMIS BIOSYN LIMITED**

CIN: L24230GJ1981PLC004878

69/C, GIDC Industrial Estate, Vapi - 396 195, Dist. Valsad, Gujarat


Tel: +91 260 2430027 Fax: +91 260 2400639 E-mail: admin@gtbl.co.in Wbsite: www.gtbl.in

**Statement of Unaudited Financial Results for the Quarter ended June 30, 2017**

	Particulars	Quarter Ended	
		30-Jun-17	30-Jun-16
		(Unaudited)	(Unaudited)
1	Revenue from operations	948.04	836.35
2	Other Income	4.08	21.49
3	<b>Total Revenue (1 + 2)</b>	<b>952.12</b>	<b>857.84</b>
4	<b>Expenses</b>		
	(a) Cost of raw materials consumed	56.16	7.78
	(b) Purchases of stock-in-trade	-	-
	(c) Changes in inventories of finished goods,work-in-progress and stock-in-trade	-	-
	(d) Excise Duty	6.34	-
	(e) Employee benefits expense	109.39	103.63
	(f) Finance Costs	9.45	7.30
	(g) Depreciation and amortisation expense	28.19	27.00
	(h) Other expenses		
	i) Stores & Spares	59.62	73.84
	ii) Power	364.63	317.32
	iii) Fuel	90.36	101.62
	iv) Water	14.92	12.74
	v) Other Expenditure	98.25	61.25
	<b>Total Expenses</b>	<b>837.30</b>	<b>712.48</b>
5	<b>Profit / (Loss) before exceptional items and Tax (3 - 4)</b>	<b>114.82</b>	<b>145.36</b>
6	Exceptional item	-	-
7	<b>Profit / (Loss) before Tax (5 - 6)</b>	<b>114.82</b>	<b>145.36</b>
8	<b>Tax expense</b>		
	(a) Current Tax	23.80	13.10
	(b) Deferred Tax	(0.39)	2.04
9	<b>Net Profit / (Loss) for the period (7 - 8)</b>	<b>91.41</b>	<b>130.22</b>
10	<b>Other Comprehensive Income</b>		
a)	Items that will not be classified to Profit & Loss		
	(i) Remeasurements of post-employment benefit obligations (gain)/loss	-	-
	(ii) Income tax relating to Items that will not be classified to Profit & Loss	-	-
b)	Items that will be classified to Profit & Loss	-	-
11	<b>Total Comprehensive Income for the Period (9 - 10)</b>	<b>91.41</b>	<b>130.22</b>
12	<b>Paid-up equity share capital</b>		
	Face Value Rs.5/- per share each	726.40	726.40
13	<b>Earnings per share</b>		
	Face Value Rs.5/- per share each (not annualised):		
	(a) Basic	0.63	0.90
	(b) Diluted	0.63	0.90

See accompanying notes to Financial Results



Notes :																					
1	The above results were reviewed by the Audit Committee and approved by the Board of Directors at its their respective meetings held on September 4, 2017. The results for the quarter ended June 30, 2017 have been reviewed by the Statutory Auditors of the Company. The Ind AS compliant corresponding figures of the quarter ended June 30, 2016 have not been subjected to limited review by the Statutory Auditors. The management has exercised necessary due diligence to ensure that such Financial Results provide a true and fair view of the affairs of the Company.																				
2	The company adopted Indian Accounting Standards (Ind AS) for the first time effective from April 1, 2017 with a transition date of April 1, 2016 and accordingly, the above Unaudited Financial Results for the quarter ended June 30, 2017 have been prepared in accordance with the recognition and measurement principals laid down in the Ind AS prescribed under section 133 of the Companies Act, 2013 read with Companies (Indian Accounting Standards) Rules, 2015 and other recognised accounting practices and policies to the extent applicable. Consequently, results for the quarter ended June 30, 2016 have been restated to comply with Ind AS to make those comparable.																				
3	Operating segments are reported in a manner consistent with the internal reporting provided to the Chief Operating Decision Maker ("CODM") of the Company. The CODM, who is responsible for allocating resources and assessing performance of the operating segments, has been identified as the Chief Executive Officer (CEO) of the Company. The Company operates only in one Business Segment i.e. manufacturing Bulk Drugs for its own and on job work basis for others within India, hence does not have any reportable Segments as per Indian Accounting Standard 108 "Operating Segments".																				
4	During the quarter, the Company has provided the gratuity expense of Rs.1.85 lakhs (Rs.2.39 lakhs for the quarter ended June 30, 2016) and leave encashment expense of Rs.1.73 lakhs (Rs.1.14 lakhs for the quarter ended June 30, 2016) on estimated basis and not on actuarial basis, which is not in accordance with Indian Accounting Standard 19 "Employee Benefits". Management does not expect any material impact of the same on the financial results. Accordingly, reclassification on account of remeasurement of post-employment benefit obligations (gain)/loss in respect of gratuity, an item that will not be classified to Profit & Loss under the head 'Other Comprehensive Income' has not been made.																				
5	In respect of Auditor's qualifications / observations in the Audit Report for the year ended March 31, 2017 that, <ol style="list-style-type: none"> <li>The outstanding balances as at March 31, 2017 in respect of certain balances of loans &amp; advances, trade receivables, liability for expenses, trade payables and creditors for capital expenditure are subject to confirmation from respective parties and consequential reconciliation and adjustment arising there from, if any, consequential impact thereof in the financial statements is not ascertainable. The Management does not expect any material variation in the financial statements.</li> <li>The Company is in the process of determining and identifying significant components of fixed assets as prescribed under the provisions of para 4(a) under the heading Notes after Part C in Schedule II of the Companies Act, 2013 and Indian Accounting Standard (Ind AS) 16 - "Property, Plant and Equipment" and hence no effect of the same has been given in the financial result for the year ended March 31, 2017. Management expects that this would not have a material impact on depreciation for the year ended March 31, 2017.</li> </ol>																				
6	Reconciliation of total comprehensive income for the quarter ended June 30, 2016: <table border="1" style="width: 100%; margin-top: 10px;"> <thead> <tr> <th style="text-align: left;">Nature of Adjustments</th> <th style="text-align: right;">Rs. in Lakhs Quarter Ended 30-Jun-16</th> </tr> </thead> <tbody> <tr> <td><b>Net Profit /(loss) for the period as per Previous GAAP (Indian GAAP)</b></td> <td style="text-align: right;"><b>112.75</b></td> </tr> <tr> <td><b>Adjustments:</b></td> <td></td> </tr> <tr> <td>Less: Prior period adjustment</td> <td style="text-align: right;">(0.10)</td> </tr> <tr> <td>Add: Gain on fair valuation of interest free Loan</td> <td style="text-align: right;">19.61</td> </tr> <tr> <td>Less: Deferred tax impact on above adjutmets (net) *</td> <td style="text-align: right;">(2.04)</td> </tr> <tr> <td><b>Net Profit /(loss) for the period as per Ind AS</b></td> <td style="text-align: right;"><b>130.22</b></td> </tr> <tr> <td>Total Other Comprehensive Income, net of tax</td> <td style="text-align: right;">-</td> </tr> <tr> <td><b>Total Comprehensive Income as per Ind AS</b></td> <td style="text-align: right;"><b>130.22</b></td> </tr> <tr> <td colspan="2">* at applicable Minimum Alternate Tax (MAT) rate</td> </tr> </tbody> </table>	Nature of Adjustments	Rs. in Lakhs Quarter Ended 30-Jun-16	<b>Net Profit /(loss) for the period as per Previous GAAP (Indian GAAP)</b>	<b>112.75</b>	<b>Adjustments:</b>		Less: Prior period adjustment	(0.10)	Add: Gain on fair valuation of interest free Loan	19.61	Less: Deferred tax impact on above adjutmets (net) *	(2.04)	<b>Net Profit /(loss) for the period as per Ind AS</b>	<b>130.22</b>	Total Other Comprehensive Income, net of tax	-	<b>Total Comprehensive Income as per Ind AS</b>	<b>130.22</b>	* at applicable Minimum Alternate Tax (MAT) rate	
Nature of Adjustments	Rs. in Lakhs Quarter Ended 30-Jun-16																				
<b>Net Profit /(loss) for the period as per Previous GAAP (Indian GAAP)</b>	<b>112.75</b>																				
<b>Adjustments:</b>																					
Less: Prior period adjustment	(0.10)																				
Add: Gain on fair valuation of interest free Loan	19.61																				
Less: Deferred tax impact on above adjutmets (net) *	(2.04)																				
<b>Net Profit /(loss) for the period as per Ind AS</b>	<b>130.22</b>																				
Total Other Comprehensive Income, net of tax	-																				
<b>Total Comprehensive Income as per Ind AS</b>	<b>130.22</b>																				
* at applicable Minimum Alternate Tax (MAT) rate																					
7	The figures of previous periods' have been regrouped / rearranged wherever necessary / practicable to conform to current periods' presentation.																				
<p>By order of the Board For GUJARAT THEMIS BIOSYN LTD.</p>  <p>Dr. DINESH PATEL Chairman DIN:00033273</p>																					
<p>Place : Mumbai Date : September 4, 2017</p>																					